Highlights |
|
In the treatment of non-melanoma skin cancer, "the fastest-moving area—and the neatest from a science standpoint—is the class of drugs called hedgehog pathway inhibitors." Why? |
|
Beyond the current approaches, recent phase 3 data has become available on a new topical while another injectable drug is under development, and both appear very promising. Exciting results. |
|
Perhaps the most valuable pearl discussed in a seminar presented by Gary Goldenberg, M.D., was a unique new topical combo treatment for psoriasis vulgaris. How it's different. |
More on Hedgehog Pathway Inhibitors, atopic dermatitis |
|
New targeted agents are changing how physicians approach therapy. Read how. |
|
Advances in research have led to the emergence of medical therapies for BCCs; more research is needed to develop systemic therapies to treat SCCs. Read more |
|
Older, non-specific immunomodulatory drugs and off-label use of several biologic agents offer treatment options for children with severe atopic dermatitis (AD). However, the future should bring therapies specifically developed for children.
Read more |
FOLLOW US ON TWITTER |
|
Follow us at @DermTimesNow
to engage with us about the show.
|
|
|
We welcome your feedback!
Please send your comments to:
Heather Onorati
Group Content Director
Dermatology Times
honorati@advanstar.com |
DISCLAIMER:
This information has been independently developed and provided by the editors of Dermatology Times. The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources. These articles may discuss regimens that have not been approved by the FDA. For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences, please see the appropriate manufacturer's product circular. |
|
